Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxSen's polio vaccine is a live-attenuated viral vaccine designed to induce protective immunity against poliomyelitis. Developed by VaxSen, a biotechnology company based in Senegal, this oral poliovirus vaccine (OPV) contains weakened strains of the poliovirus that replicate in the gastrointestinal tract. This replication stimulates a comprehensive immune response, including the production of systemic antibodies and local mucosal IgA, which is essential for preventing both the disease and the transmission of the virus. The development of this vaccine is part of VaxSen's broader mission to enhance vaccine manufacturing autonomy in Africa and support global efforts to eradicate polio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaxsen polio vaccine.